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a b s t r a c t
Vesicular stomatitis virus (VSV) is an effective oncolytic virus against most human pancreatic ductal
adenocarcinoma (PDAC) cell lines. However, some PDAC cell lines are highly resistant to oncolytic VSV-
ΔM51 infection. To better understand the mechanism of resistance, we tested a panel of 16 small
molecule inhibitors of different cellular signaling pathways, and identiﬁed TPCA-1 (IKK-β inhibitor) and
ruxolitinib (JAK1/2 inhibitor), as strong enhancers of VSV-ΔM51 replication and virus-mediated
oncolysis in all VSV-resistant PDAC cell lines. Both TPCA-1 and ruxolitinib similarly inhibited STAT1
and STAT2 phosphorylation and decreased expression of antiviral genes MxA and OAS. Moreover, an
in situ kinase assay provided biochemical evidence that TPCA-1 directly inhibits JAK1 kinase activity.
Together, our data demonstrate that TPCA-1 is a unique dual inhibitor of IKK-β and JAK1 kinase, and
provide a new evidence that upregulated type I interferon signaling plays a major role in resistance of
pancreatic cancer cells to oncolytic viruses.
& 2015 Elsevier Inc. All rights reserved.
Introduction
The use of oncolytic viruses (OVs) as an anticancer strategy
arises from their ability to infect, replicate in and kill cancer cells.
Compared to non-malignant cells, cancer cells are generally more
susceptible to viral infection due to their defects in type I
interferon (IFN)-mediated antiviral responses [reviewed in
(Barber, 2005; Hastie et al., 2013; Lichty et al., 2004)]. Vesicular
stomatitis virus (VSV, a rhabdovirus) is a promising OV success-
fully used in preclinical models for the treatment of a variety of
cancers, and currently in a phase I clinical trial for treatment of
hepatocellular carcinoma (clinical trial NCT01628640). Pancreatic
ductal adenocarcinoma (PDAC) comprises about 95% of pancreatic
cancers and is highly invasive with aggressive local growth and
rapid metastases to surrounding tissues. Standard cancer therapies
show little efﬁcacy in treating PDAC (Stathis and Moore, 2010). Our
recent studies demonstrated that VSV recombinants are effective
against a majority of clinically relevant human PDAC cells lines
tested (Murphy et al., 2012). However, out of 11 human PDAC
cell lines, 4 were resistant to VSV infection, replication and
virus-mediated oncolysis (Murphy et al., 2012). In all VSV-
resistant cell lines several interferon stimulated genes (ISGs),
including the antiviral genes MxA and OAS, were constitutively
expressed at high-level, and inhibition of type I IFN signaling
pathway using JAK Inhibitor I (JAK Inh. I, a pan-JAK inhibitor)
reduced ISG expression and decreased their resistance to VSV
(Moerdyk-Schauwecker et al., 2013).
In the present study, to better understand the mechanism of
the resistance and ﬁnd new approaches to overcome it, we
tested a panel of 16 inhibitors of different cellular signaling
pathways previously shown to affect replication of VSV and
other viruses. Our experiments identiﬁed one inhibitor of IkB
kinase β (IKK-β), TPCA-1, and one selective JAK1/2 inhibitor,
ruxolitinib (trade name Jakaﬁ) that decreased levels of ISGs and
increased VSV replication and VSV-mediated oncolysis more
efﬁciently than JAK Inhibitor I. Further studies provided evi-
dence that IKK-β inhibitor TPCA-1 also functions as a direct
inhibitor of JAK1 kinase. Together, our data show that TPCA-1 is
a unique dual inhibitor of IKK-β and JAK1 kinase, and provide a
new evidence that the upregulated type I interferon signaling
plays a major role in resistance of pancreatic cancer cells to
oncolytic viruses.
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Results
Identiﬁcation of TPCA-1 and ruxolitinib as effective enhancers of VSV
replication in VSV-resistant HPAF-II cells
We have shown previously that 4 out of 11 tested human PDAC
cell lines were resistant to VSV infection (Moerdyk-Schauwecker
et al., 2013; Murphy et al., 2012), at least in part due to constitutive
high-level expression of ISGs (Moerdyk-Schauwecker et al., 2013).
Pretreatment of resistant cell lines with JAK Inh. I (a reversible
inhibitor of JAK1, JAK2, JAK3 and TYK2) reduced ISG expression and
partially overcame resistance to VSV (Moerdyk-Schauwecker et al.,
2013), suggesting potential for further improvement by utilizing other
inhibitors and/or targeting additional pathways. Therefore, in the
present study we tested a panel of 16 inhibitors targeting different
pathways, shown to directly or indirectly affect ISG expression and/or
replication of VSV or other viruses in other experimental systems. As a
positive control we included JAK Inh. I. In addition, we included
ruxolitinib (INCB018424, trade name Jakaﬁ), a selective inhibitor of
JAK1 and JAK2. We also tested two histone deacetylase (HDAC)
inhibitors, SAHA (also known as Vorinostat), and valproic acid
(VPA), both previously shown to inhibit ISG expression and enhance
VSV replication in other systems (Chang et al., 2004; Nguyên et al.,
2008; Shulak et al., 2014). As the NF-κB signaling pathway was
reported to affect IFN regulated gene expression (Pfeffer et al., 2004),
the following inhibitors affecting different factors/steps in the NF-κB
signaling pathway were included: eight IKK inhibitors (TPCA-1,
SC-514, IKK-16, IKK Inh. XIII, IMD-0354, BMS-345541, IKK-2 Inh. VIII,
and sulfasalazine); a 20S proteosome inhibitor (bortezomib); a MEK1/
2 inhibitor (U-0126); a mTOR inhibitor (rapamycin); and a COX-2
inhibitor (celecoxib).
VSV-ΔM51-GFP, which has a deletion of the methionine at amino
acid position 51 of the matrix protein, and the green ﬂuorescent
protein (GFP) ORF inserted at position 5 of the viral genome (between
the VSV G and L genes) (Wollmann et al., 2010) was used in this study.
The ΔM51 and other M51 mutations in the VSV matrix protein
prevent the ability of wild type (wt) matrix protein to shut down
expression of antiviral genes (Ahmed et al., 2003; Kopecky et al.,
2001; Stojdl et al., 2003). Therefore, VSV-ΔM51 is unable to success-
fully replicate in healthy cells with intact type I IFN responses.
However, as many cancer cells have defective type I IFN signaling
(Obuchi et al., 2003), they remain susceptible to VSV-ΔM51 infection.
VSV recombinants with M51 mutation are some of the best perform-
ing oncolytic VSVs [reviewed in (Hastie and Grdzelishvili, 2012)], and,
compared to wt VSV (Bi et al., 1995; Reiss et al., 1998; van den Pol et
al., 2002), they show a signiﬁcantly improved oncoselectivity and
decreased neurotoxicity (Stojdl et al., 2003; Wollmann et al., 2010).
The screening of the inhibitors was conducted on one of the
most VSV-resistant human PDAC cell lines, HPAF-II (Moerdyk-
Schauwecker et al., 2013; Murphy et al., 2012). Cells were treated
with each inhibitor at different concentrations based on previously
reported effective doses. Following inhibitor treatment for 48 h,
cells were infected with VSV-ΔM51-GFP at MOI of 0.001. VSV-
driven GFP ﬂuorescence was measured for 5 days p.i. (Fig. 1A and
Supplementary Fig. 1A) and cell viability was determined at 5 days
p.i. by MTT assay (Fig. 1B and Supplementary Fig. 1B).
In agreement with our previous study (Moerdyk-Schauwecker et al.,
2013), JAK Inh. I treatment increased VSV-driven GFP ﬂuorescence
(Fig. 1A). A similar enhancement of VSV replication was shown for
ruxolitinib, which was previously shown to break resistance of human
head and neck cancer cells to VSV (Escobar-Zarate et al., 2013), but has
never been tested in combination with VSV in PDAC cells. It should be
noted that at the highest concentration tested, ruxolitinib was highly
toxic to the cancer cells (Fig. 1B). The HDAC inhibitor SAHA (8 μM)
showed a small effect, which was statistically signiﬁcant but 25-fold less
effective compared to ﬂuorescence values reached by treatment with
JAK Inh. I or ruxolitinib (Supplementary Fig. 1A). Surprisingly, among the
inhibitors targeting the NF-κB pathway, only one, TPCA-1, increased
VSV-driven GFP ﬂuorescence and matched levels achieved with the JAK
inhibitors (JAK Inh. I and ruxolitinib) (Supplementary Fig. 1A). The effect
of TPCA-1 treatment on VSV replication was conﬁrmed with TPCA-1
purchased from two different providers (data not show).
Importantly, increase in VSV-driven GFP expression in HPAF-II
cells treated with TPCA-1, ruxolitinib or JAK Inh. I directly
correlated with increases in new viral particle production
(Fig. 1C). Percentage of GFP positive cells measured by ﬂow
cytometry at 48 h p.i. showed an increase from 1.7% for cells
treated with no drug to 99.1%, 98.7% and 89.2% for TPCA-1,
ruxolitinib and JAK Inh. I treatment, respectively (Fig. 1D).
When VSV-mediated cell killing was determined by MTT, striking
decreases of 83%, 90%, and 86% in cell viability were observed for JAK
Inh. I (5 μM), ruxolitinib (8 μM) and TPCA-1 (8 μM) treatments,
respectively, compared to uninfected cells (Fig. 1B). Treatment with
SAHA (8 μM) caused a decrease in cell viability comparable to TPCA-1
(8 μM), even though its effect on VSV-driven GFP ﬂuorescence was
marginal (Supplementary Fig. 1A and B). This suggests epigenetic
modiﬁcations of chromatin may affect VSV induced cell death
independently of viral replication. While treatments with IKK Inh.
XIII (0.8 μM), BMS-345541 (4 μM), and rapamycin (80, 8 and 0.8 nM)
also showed statistically signiﬁcant decrease in cell viability of
infected compared to uninfected cells (21%, 33%, and up to 26%,
respectively), these were not as pronounced as the effect of TPCA-1,
ruxolitinib or JAK Inh. I treatment (Supplementary Fig. 1B).
As all inhibitors, except JAK Inh. I, rapamycin, celecoxib and
VPA, showed signiﬁcant toxicity in uninfected cells at the highest
tested concentrations compared to uninfected cells treated with
no drug, it is unlikely that any of the ineffective inhibitors would
enhance VSV replication at even higher concentrations (Supple-
mentary Fig. 1B).
TPCA-1 and ruxolitinib overcome resistance to VSV in all VSV-
resistant PDAC cell lines
To determine if the enhancement of VSV replication by TPCA-1
and ruxolitinib was limited only to HPAF-II cells, we tested these
inhibitors as well as JAK Inh. I in three additional VSV-resistant
PDAC cell lines, Hs766T cells (shows a high resistance to VSV,
similar to HPAF-II), CFPAC-1 and HPAC (both show an intermediate
resistance to VSV) (Moerdyk-Schauwecker et al., 2013; Murphy
et al., 2012). Cells were treated with 4 different concentrations of
TPCA-1, ruxolitinib or JAK Inh. I for 48 h prior to infection with
VSV-ΔM51-GFP at an MOI of 1.5 (based on titration on BHK-21
cells. Fig. 2 legend indicates cell speciﬁc MOIs). TPCA-1, ruxolitinib,
and JAK Inh. I, enhanced VSV-ΔM51-GFP replication in all VSV-
resistant PDAC cell lines (Fig. 2A). The observed lack of a dose-
dependent response in some of the cell lines may be due to the
narrow range of drug dilutions used in this experiment. For
example, there was no dose-dependent effect for ruxolitinib in
HPAF-II cells in Fig. 2A (2-fold dilution), but clearly showed a dose
dependency when tested at 10-fold dilution (Fig. 1A). In agree-
ment with GFP ﬂuorescence data, for all VSV-resistant PDAC cell
lines, treatment with TPCA-1, ruxolitinib and JAK Inh. I caused
strong decrease in cell viability in all VSV infected cells compared
to uninfected cells (Fig. 2B). Together, our results show that
TPCA-1, ruxolitinib and JAK Inh. I are effective in overcoming
resistance to VSV in all identiﬁed VSV-resistant PDAC cell lines.
Treatment with TPCA-1, ruxolitinib or JAK Inh. I immediately post
infection is sufﬁcient to increase VSV replication
Our previous experiments with JAK Inh. I (Moerdyk-Schauwecker
et al., 2013) and those presented above were performed by pre-
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treating cells with inhibitors for 48 h prior to infection. To examine
the treatment schedule required to overcome resistance of PDAC cells
to VSV, Hs766T and HPAF-II cells were treated with TPCA-1 (8 μM),
ruxolitinib (2.5 μM) or JAK Inh. I (2.5 μM) for either one or two days
prior to infection with VSV-ΔM51-GFP at MOI of 1.5 (based on
titration on BHK-21 cells. Fig. 3 legend indicates cell speciﬁc MOIs),
and treatment was maintained for 5 days p.i. or removed right after
infection. Alternatively, inhibitors were not added before infection but
TPCA-1
Ruxolitinib
JAK Inh. I
no drug
+VSV-ΔM51-GFP
VSV + TPCA-1
VSV + Ruxolitinib VSV + JAK Inh. I
Uninfected VSV
%
%%
1.7%
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instead were added right after infection and maintained for 5 days
(Treatment Schedule in Fig. 3A).
In both Hs766T and HPAF-II, a strong increase in VSV-driven
GFP ﬂuorescence was observed only when treatment was main-
tained after infection, regardless of when treatment was applied
(GFP ﬂuorescence in Fig. 3A; treatment schedules 1, 2 and 5).
However, cells remained resistant to VSV infection if treatment
was removed before infection (GFP Fluorescence in Fig. 3A; treat-
ment schedules 3 and 4). In Hs766T cell, the absence of treatment
before infection (GFP Fluorescence in Fig. 3A; treatment schedule
5) delayed the increase in GFP ﬂuorescence by 16 h for TPCA-1 and
JAK Inh. I (but not for ruxolitinib), suggesting the uptake/activation
of ruxolitinib is faster than for the other two inhibitors. In contrast,
no difference was observed between the three inhibitors in
HPAF-II cells. In agreement with these results, MTT assay at
day 5 p.i. showed a dramatic decrease in cell viability in VSV-
infected cells when inhibitor treatments were maintained after
infection, regardless of the presence of inhibitors prior to infection
(Cell viability in Fig. 3A). In general, for all three inhibitors, this
experiment indicates that treatment before infection is not as
critical as treatment immediately after infection.
To determine the optimal duration for treatment p.i., HPAF-II
cells were treated with each of the inhibitors for one-day before
infection, and then the treatment was either removed immedi-
ately after infection, or kept for different periods of time up to
5 days p.i. (Treatment Schedule in Fig. 3B). All inhibitors were
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Fig. 2. Effect of TPCA-1, ruxolitinib and JAK Inh. I on four different VSV-resistant PDAC cell lines. CFPAC-1, HPAC, Hs766T and HPAF-II cells were treated with TPCA-1,
ruxolitinib or JAK Inh. I for 48 h before infection with VSV-ΔM51-GFP at MOI 1.5 (based on BHK-21 cells). Cell speciﬁc MOIs are MOI 0.008 based on CFPAC, MOI 0.005 based
on HPAC, MOI 0.003 based on Hs766T and MOI 0.001 based on HPAF-II. (A) GFP ﬂuorescence was measured and background ﬂuorescence from uninfected treated cells was
subtracted at each time point p.i. (*) indicates statistical signiﬁcance (po0.05) between treatment and no treated cells (0 μM) at 48 h p.i. (B) Cell viability was analyzed by
MTT assay at 5 days p.i., and is expressed as percent of the uninfected treated with no drug control. Results in each row correspond to the same cell line as in A. The assays
were done in triplicate and data represent the mean7SD of mean. (*) indicates statistical signiﬁcance (po0.05) between infected and uninfected cells within the same
treatment.
Fig. 1. Effect of TPCA-1, ruxolitinib and Jak Inh. I on VSV-infected HPAF-II. (A) Cells were treated with serial dilutions of each inhibitor for 48 h prior infection with VSV-
ΔM51-GFP (cell speciﬁc MOI 0.001). GFP ﬂuorescence was measured and background ﬂuorescence from uninfected treated cells was subtracted at each time point p.i. (*)
indicates statistical signiﬁcance (po0.05) between treatment and no treated cells (0 μM) at 48 and 72 h p.i. (B) Cell viability was analyzed by MTT assay at 5 days p.i. and is
plotted as percentage of the uninfected treated with no drug control. The assays were done in triplicate and data represent the mean7SD of mean. (*) indicates statistical
signiﬁcance (po0.05) between infected and uninfected cells within the same treatment. (C) Cells were infected with VSV-ΔM51-GFP at cell speciﬁc MOI 0.01 for 1 h, then
treated with TPCA-1 (8 μM), ruxolitinib (2.5 μM) or JAK Inh. I (2.5 μM). Treatment was maintained until the end of the experiment. GFP ﬂuorescence was measured at the
speciﬁed time point p.i. (*) indicates statistical signiﬁcance (po0.05) between treatment and no treated cells (no drug) at 48 and 72 h p.i. Media from infected cells were
collected at 8, 24, 48, and 72 h p.i. and new infectious viral particle productionwas determined by plaque assay on BHK-21 cells. Titers were determined in duplicate and data
represent the mean7SD of mean. (*) indicates statistical signiﬁcance (po0.05) between inhibitor treated and untreated (no drug) cells within the same time point p.i.
(D) Cells were treated with no drug or with TPCA-1 (8 μM), ruxolitinib (2.5 μM), or JAK Inh. I (2.5 μM) for 48 h before infection with VSV-ΔM51-GFP (cell speciﬁc MOI 0.001).
Percentage of GFP positive cells was determined by ﬂow cytometry at 48 h p.i. Gated populations are positive for GFP. The assay was done in triplicate and data represent the
mean7SD of mean.
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ineffective if removed prior to infection (GFP Fluorescence in
Fig. 3B; treatment schedule 1). However, when treatment was
maintained for 1 day p.i., GFP ﬂuorescence increased up to 1.7-fold
with TPCA-1 and ruxolitinib, and up to 1.5-fold with JAK Inh. I.
(GFP Fluorescence in Fig. 3B; treatment schedule 2). GFP ﬂuores-
cence was maximally increased (up to 3-fold with TPCA-1 and
ruxolitinib and up to 2.5-fold with JAK Inh. I) when treatment was
maintained more than 1 day p.i. (GFP Fluorescence in Fig. 3B;
treatment schedules 3–6).
Together our data suggest that TPCA-1, ruxolitinib and JAK Inh. I
in HPAF-II and Hs766T cells reversibly inhibit their targets and
enhance VSV replication, but are not effective if removed prior to
viral exposure.
TPCA-1 and ruxolitinib decrease expression of antiviral ISGs MxA and
OAS in uninfected HPAF-II cells
Our screening identiﬁed TPCA-1 and ruxolitinib as effective
enhancers of VSV replication and VSV-mediated oncolysis in VSV-
resistant PDAC cell lines. The identiﬁcation of ruxolitinib, a JAK1/2
inhibitor, is expected as it acts similarly to the less speciﬁc pan-JAK
inhibitor, JAK Inh. I. More surprisingly TPCA-1, a selective inhibitor
of IKK-β (Birrell et al., 2005; Birrell et al., 2006; Podolin et al.,
2005), was the only inhibitor targeting the NF-κB, that was able to
enhance VSV replication. To determine the impact of inhibitors on
constitutive ISG expression, we analyzed the expression of MxA
and OAS at 48 h post-inhibitor treatment in uninfected HPAF-II
cells (Fig. 4A). As expected, inhibition of the JAK/STAT signaling
pathway by JAK Inh. I or ruxolitinib almost completely eliminated
MxA protein levels and markedly reduced OAS protein levels
compared to cells treated with no drug. Importantly, a similar
effect on MxA and OAS was seen in TPCA-1 treated cells. On the
other hand, the others IKK-β inhibitors, IKK-16, IKK Inh. XIII, and
BMS-345541, did not affect levels of MxA or OAS protein. Inter-
estingly, sulfasalazine (an IKK-α/β inhibitor) also decreased MxA
and OAS protein levels, however, possibly to a degree not sufﬁcient
to affect VSV-driven GFP ﬂuorescence or VSV-mediated cell death
(Supplementary Fig. 1). Surprisingly, even though treatment with
SAHA (an HDAC inhibitor) caused the strongest decrease in MxA
and OAS protein level (Fig. 4A), it only showed a very minor
increase on VSV-driven GFP ﬂuorescence (Supplementary Fig. 1A).
It is possible that large epigenetic modiﬁcations associated with
SAHA treatment, while strongly down regulating MxA and OAS,
may also negatively affect other aspects of the virus replication
Fig. 3. Effect of inhibitor treatment timings on VSV infection and oncolysis in VSV-resistant PDAC cells. (A) HPAF-II and Hs766T cells were seeded 3 days before infection (d-3)
and treated with TPCA-1 (8 μM), ruxolitinib (2.5 μM) or JAK Inh. I (2.5 μM) for 0, 1, or 2 days before infection with VSV-ΔM51-GFP at MOI 1.5 (based on BHK-21 cells). Cell
speciﬁc MOIs are MOI 0.003 based on Hs766T and MOI 0.001 based on HPAF-II. Virus was removed after 1 h and replaced with either media with inhibitor or no drug (see
Treatment Schedule). GFP ﬂuorescence was measured at each time point p.i. Statistical signiﬁcances (po0.05) between treatment schedules and the treatment schedule 6
(no drug) at 48 (*) and 72 (#) h p.i. are indicated. Cell viability was analyzed in HPAF-II cells by MTT assay at 120 h p.i., and is showed as percentage of cells treated with no
drug. The assays were done in triplicate and data represent the mean7SD of mean. (*) indicates statistical signiﬁcance (po0.05) between inhibitor treated and untreated
cells (no drug) within the same treatment schedule. (B) HPAF-II cells were seeded 2 days before infection (d2) and treated with TPCA-1 (8 μM), ruxolitinib (2.5 μM) or JAK
Inh. I (2.5 μM) for 1 day before infection with VSV-ΔM51-GFP (cell speciﬁc MOI 0.001). Virus was removed after 1 h and replaced with either media with inhibitor or no drug.
Every 24 h p.i. media was removed and replaced with either media with inhibitor or no drug (see Treatment Schedule). GFP ﬂuorescence was measured at each time point p.
i. The assays were done in triplicate and data represent the mean7SD of mean. Statistical signiﬁcances (po0.05) between treatment schedules and the treatment schedule
7 (no drug) at 48 h (*) and 72 h (#) are indicated.
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cycle. Future studies will examine the impact of SAHA on ISG
expression and VSV replication in PDAC cells.
Of the tested IKK inhibitors, TPCA-1 was the only one enhan-
cing VSV replication. This could be due to the lack of uptake or
activity of other IKK inhibitors in HPAF-II cells, or if TPCA-1 affects
other targets in addition (or instead) of IKKs. To examine if tested
IKK inhibitors which did not show any effect (Supplementary
Fig. 1) were active in HPAF-II cells, we determined the effect of
these inhibitors on TNF-α-mediated induction of TNF-αmRNA (an
NF-κB dependent gene) and IFN-α-mediated induction of MxA
mRNA (Fig. 4B). Semi-quantitative RT-PCR results showed that at
least 5 out of all 7 IKK inhibitors effectively blocked induction of
TNF-α-mediated TNF-α mRNA synthesis. Together, these results
demonstrate that TPCA-1 is the only one of the tested IKK
inhibitors capable to simultaneously inhibit NF-κB pathway and
IFN-mediated ISGs expression in PDAC cells, while enhancing VSV
replication.
Combining TPCA-1 with ruxolitinib or JAK Inh. I has no cooperative
effect on VSV replication or ISG expression
Next, we wanted to examine whether TPCA-1 and JAK inhibitors
affect VSV replication and ISG expression via the same or different
mechanism. We hypothesized that if TPCA-1 and JAK inhibitors
enhance VSV replication via different mechanisms, combining them
would have an additive or synergistic effect on VSV replication. HPAF-
II and Hs766T cells were treated with no drug or either with TPCA-1
(8 μM), ruxolitinib (2 μM) or both inhibitors together. One day after
treatment, cells were infected with VSV-ΔM51-GFP at MOI of 0.001.
After infection, treatments were maintained for 4 days and VSV-
driven GFP ﬂuorescence was measured every 24 h. As shown in
Fig. 5A, VSV-driven GFP ﬂuorescence measured from cells treated
with both inhibitors reached intermediate values compared to each
inhibitor alone, indicating no additive or synergistic effect of this
combined treatment.
To examine the effect of the TPCA-1/ruxolitinib combination in
more detail, each inhibitor was used at four different concentrations
for a total of 16 combination treatments. One day after treatment,
cells were infected with VSV-ΔM51-GFP at an MOI of 0.001,
and VSV-driven GFP ﬂuorescence was measured at 2 days p.i.
Combination Index (CI) values were calculated for each combined
treatment by the method of Chou and Talalay (Chou, 2006; Chou
and Talalay, 1984) (Fig. 5B). For all but the lowest concentrations, CI
values were greater than 1, indication of an antagonistic effect.
Speciﬁcally, for the optimal concentration determined for each
inhibitor and used throughout our studies (8 μM for TPCA-1 and
2.5 μM for ruxolitinib), the CI values were 2.64 and 1.77 for HPAF-II
and Hs766T, respectively. An antagonistic effect suggests that both
inhibitors affect the same downstream target(s) essential for VSV
replication with the combination causing an effect(s) that nega-
tively impacts virus replication and partially counteracts the posi-
tive effects seen during monotherapy.
Similar results were obtained with a TPCA-1 and JAK Inh. I
combination in HPAF-II, HPAC, and Hs766T cells (Fig. 5C). Despite
targeting two different signaling pathways in the cell, JAK Inh. I
and TPCA-1 showed similar decreases in MxA expression and
increases in VSV protein expression. BMS-345541 (BMS) was also
included as an example of an IKK inhibitor with no effect on VSV
replication and ISG expression.
TPCA-1 downregulates type I IFN-mediated JAK/STAT signaling
pathway by directly inhibiting JAK1
Next, we examined in more detail how mechanistically TPCA-1
could inhibit ISG expression. First, we analyzed how activation and
inhibition of type I IFN and NF-κB pathways affect expression of MxA
and OAS. HPAF-II cells were treated with no drug or with TPCA-1 or
ruxolitinib for 2 h then activated with either IFN-α or TNF-α for 4 h
(Fig. 6A). Gene expression was determined by real-time PCR and
normalized to the expression of GAPDH. In cells without TPCA-1 or
ruxolitinib treatment, IFN-α induced a strong increase in MxA and OAS
expression but showed no effect on TNF-α expression, a gene under
control of the NF-κB pathway. Conversely, TNF-α treatment upregu-
lated TNF-α expression, but did not affect MxA or OAS expression. This
result shows that activation of the NF-κB pathway does not result in
MxA and OAS expression in HPAF-II cells, suggesting that NF-κB
pathway does not play a major role in the expression of these ISGs.
As expected, TPCA-1 (but not ruxolitinib) inhibited constitutive as well
as TNF-α induced expression of TNF-α, and ruxolitinib signiﬁcantly
inhibited constitutive as well as IFN-α induced expression of MxA and
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Fig. 4. Effect of inhibitors on protein and mRNA levels in HPAF-II. (A) Cells were treated with TPCA-1 (8 μM), IKK-16 (0.8 μM), IKK Inh. XIII (0.8 μM), IKK-2 Inh. VIII (8 μM),
BMS-345541 (4 μM), Sulfasalazine (4 mM), SAHA (8 μM), Celecoxib (80 μM), Rapamycin (80 nM), ruxolitinib (2.5 μM) or JAK Inh. I (2.5 μM) for 48 h. Cells lysates were
prepared and analyzed by Western blot for the indicated protein. Protein sizes (kDa) are indicated on the right. (B) Cells were treated with TPCA (8 μM), SC-514 (80 μM), IKK-
16 (0.8 μM), IKK Inh. XIII (0.8 μM), IKK-2 Inh. VIII (8 μM), IMD-0354 (0.8 μM), or BMS-345541 (4 μM) for 2 h prior to addition of TNF-α (25 ng/ml) or IFN-α (5000 U/ml). Cells
were harvested at 4 h post-induction and extracted mRNA was reverse transcribed and analyzed by PCR.
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OAS. Surprisingly, TPCA-1 also inhibited both constitutive and IFN-α
induced expression of MxA and OAS. The ability of TPCA-1 to inhibit
MxA and OAS expression even in the presence of exogenously added
IFN-α suggests that TPCA-1 affects ISG expression by directly inhibiting
IFN signaling, rather than by inhibiting IFN-β expression. It is known
that NF-κB can mediate expression of IFN-β, which acts through the
Fig. 5. Effect of TPCA-1 and JAK inhibitors combination treatment on PDAC cells. HPAF-II and Hs766T cells were treated with TPCA-1, ruxolitinib, or TPCA-1 and ruxolitinib
combined. Treatment was started 1 day before infection with VSV-ΔM51-GFP (cell speciﬁc MOI 0.001), and maintained for 4 days p.i. (A) GFP ﬂuorescence was measured and
normalized to cells treated with no drug at each time point p.i. Assays were done in triplicate and data represent the mean7SD of mean. (*) indicates statistical signiﬁcance
(po0.05) between treatment and no treated cells (no drug) at 48 and 72 h p.i. (B) Combination Indexes (CI) calculated using the method of Chou-Talalay using VSV-driven GFP
values at 48 h p.i. Range of CI is as described by Chou and Talalay (Chou, 2006). (C) HPAF-II, HPAC and Hs766T cells were treated with TPCA-1 (8 μM), JAK Inh. I (2.5 μM), BMS-
345541 (BMS) (4 μM), or TPCA-1 and JAK Inh. I combined for 2 days before infection with VSV-ΔM51-GFP at MOI 15 (based on BHK-21 cells). Cell speciﬁc MOIs are MOI 0.01
based on HPAF-II, MOI 0.05 based on HPAC, and MOI 0.03 based on Hs766T. Cells lysates were prepared 2 days p.i, and analyzed by Western blot for the indicated proteins.
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IFN-α/β receptor in an autocrine manner to maintain basal expression
of ISGs in uninfected cells (Basagoudanavar et al., 2011; Taniguchi and
Takaoka, 2001). In agreement with it, our data show that a small but
statistically signiﬁcant decrease in constitutive IFN-β expression was
observed in the presence of TPCA-1 (Fig. 6A). This suggests that TPCA-1
could affect ISGs expression by inhibiting NF-κB dependent IFN-β
expression. However, this mechanism cannot explain our result
demonstrating that TPCA-1 inhibits MxA and OAS expression even in
the presence of exogenously added IFN-α. Together, our data suggest
that TPCA-1 inhibits IFN-mediated ISG expression mainly via direct
inhibition of type I IFN signaling downstream of type I IFN production,
although TPCA-1-mediated decrease of the basal IFN-β expression
could have a minor contribution to the decreased ISG levels.
Type I IFNs (including IFN-α and IFN-β) signal primarily through
JAK/STAT pathways, although they can also activate other signaling
pathways (Bonjardim et al., 2009). Ligand binding to the IFN-α⧸β
receptor activates phosphorylation of JAK1 and TYK2, which then
phosphorylate STAT1 and STAT2, which are also bound to the IFN-α⧸β
receptor. This results in the formation of transcription factor com-
plexes, which translocate to the nucleus and promote the transcription
of ISGs. Binding of type I IFNs to their receptor most commonly results
in a transcription factor complex of IFN-regulatory factor 9 (IRF-9),
p-STAT1 and p-STAT2 (known as ISGF3), which recognizes IFN
stimulated response elements (ISRE). To further study the mechanism
by which TPCA-1 directly affects the type I IFN pathway, we analyzed
expression and phosphorylation of several proteins involved in the
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Fig. 6. TPCA-1 directly inhibits the JAK/STAT signaling pathway. HPAF-II cells were treated with TPCA-1 (8 μM), ruxolitinib (2.5 μM), or JAK Inh. I (2.5 μM) for 2 h prior to
induction with either TNF-α (25 ng/ml) or IFN-α (5000 U/ml). Cells were harvested at 4 h post-induction. (A) Relative gene expression was analyzed by real-time PCR and
normalized to GAPDH expression. Fold change expression was calculated by the comparative Ct method. (B) Cell lysates were prepared and analyzed by Western blot for the
indicated protein. Protein sizes (kDa) are indicated on the right. C) HPAF-II cells were treated with TPCA-1 (8 μM), ruxolitinib (2.5 μM), or JAK Inh. I (2.5 μM) for 2 h prior to
induction with IFN-α (5000 U/ml) for the indicated time. Cells were harvested and nuclear extracts were subjected to EMSA using a radiolabeled ISRE probe. (D) In situ
titration of TPCA-1, ruxolitinib and BMS-345541 were performed with recombinant human JAK1 kinase using a luminescent ADP detection assay. Reactions were carried out
at 5 μM ATP. The assays were done in duplicate and data represent the mean7SD of mean. Curve ﬁtting was performed using GraphPad Prism sigmoidal dose–response
(variable slope) software.
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signaling pathway (Fig. 6B). HPAF-II cells were treated with no drug or
with TPCA-1, ruxolitinib or JAK Inh. I for 2 h and then activated with
either IFN-α or TNF-α for 4 h. TPCA-1, but not ruxolitinib or JAK Inh. I,
inhibited phosphorylation of IκBα (a target of IKK-β). Phosphorylation
of IκBα is required for its proteasome-mediated degradation, resulting
in the release and nuclear translocation of active NF-κB (Brown et al.,
1995). Importantly, TPCA-1, ruxolitinib and JAK Inh. I prevented
induction of MxA and OAS by IFN-α, with TPCA-1 being the most
effective of all three. Interestingly, TPCA-1, ruxolitinib and JAK Inh. I
were able to reduce low but detectable levels of constitutively
phosphorylated STAT1 (which is also an ISG), which would account
for the effect of these inhibitors on constitutive expression of ISGs in
HPAF-II. Moreover, in the presence of ruxolitinib or JAK Inh. I IFN-α
induced activation of STAT1 and STAT 2 was markedly reduced, but it
was completely abolished in presence of TPCA-1.
We also directly tested the ability of TPCA-1, ruxolitinib and JAK
Inh. I to prevent the functional consequence of activating the type I
IFN pathway. If TPCA-1 is a direct inhibitor of IFN signaling, it
should prevent ISGF3 transcription factor nuclear re-localization
and ISRE binding following activation with IFN-α. HPAF-II cells
were treated with TPCA-1, ruxolitinib or JAK Inh. I for 2 h, followed
by 0.5 or 1 h induction with IFN-α. Nuclear extracts prepared from
these cells were incubated with a radiolabeled ISRE probe (Fig. 6C).
Formation of an IFN-α dependent complex was prevented by all
three inhibitors, suggesting that TPCA-1 inhibits type I IFN signal-
ing in a manner indistinguishable from ruxolitinib or JAK Inh. I.
To directly examine whether TPCA-1 prevents phosphorylation of
STAT1 and STAT2 via inhibition of JAK1, we performed an in situ
kinase activity assay using a puriﬁed recombinant human JAK1 in the
presence of TPCA-1, ruxolitinib or BMS-345541 (another IKK inhibi-
tor) (Fig. 6D). Ruxolitinib and TPCA-1 were able to inhibit JAK1 kinase
activity in a dose dependent manner with an IC50 of 4.33 nM and
43.78 nM, respectively, while BMS-345541 did not affect the kinase
enzymatic activity. These data provide biochemical evidence that
TPCA-1 directly inhibits JAK1 kinase, which can explain inhibition of
STAT1 and STAT2 phosphorylation in vitro (Fig. 6B).
We next investigated the effect of inhibitor treatments on the
kinetics of VSV replication, MxA expression and apoptosis induction
(Fig. 7). HPAF-II cells were infected with VSV-ΔM51-GFP at an MOI of
0.01, and immediately treated with no drug or with TPCA-1, ruxoli-
tinib or JAK Inh. I. Cell lysates were prepared at 8, 24, 48 and 72 h p.i.
and analyzed by Western blot. First, it is important to note that our
microscopic observation showed extensive cell death at 48 and 72 h
p.i. of infected cells treated with TPCA-1 and ruxolitinib (data not
shown), which explains lower levels of total protein isolated from the
corresponding cells (see protein staining in Fig. 7; an equal fraction of
total retrieved cell lysate was loaded for each sample). At all time
points after 8 h p.i. (and despite decrease in total protein loaded from
48 and 72 h p.i.), Western blot showed a dramatic increase in
accumulation of viral protein in cells treated with TPCA-1, ruxolitinib,
or JAK Inh. I. TPCA-1 and ruxolitinib also strongly inhibited STAT1 and
STAT2 phosphorylation (at all time points, including 8 and 24 h p.i.
where equal amount of total protein were loaded), as wells as total
STAT1 and STAT2 levels (after 8 h p.i.), likely accounting for stable
decrease of MxA expression (Fig. 7). On the other hand, JAK Inh. I,
while inhibiting STAT2 phosphorylation, failed to suppress STAT1
phosphorylation, total STAT1 and STAT2 expression, and MxA expres-
sion long term. However, all 3 inhibitors strongly inhibited STAT1
phosphorylation at 8 h p.i., which was likely sufﬁcient to ensure
similar high levels of VSV proteins for all 3 inhibitors. Also, despite
these differences, all three inhibitors strongly induced VSV-mediated
apoptosis, demonstrated by Caspase 3 and PARP cleavage at 24 and 48
h p.i. It should be noted that, despite the induction of apoptosis at 24
and 48 h p.i. in JAK Inh. I treated cells, loss of cells (and cell material)
was not observed at these time points (Fig. 7). However, at 120 h p.i.
cell viability was clearly reduced in JAK Inh. I treated cells (Fig. 1B).
TPCA-1, ruxolitinib and JAK Inh. I enhance replication of Sendai virus
Our data suggest that ruxolitinib and TPCA-1-mediated
enhancement of VSV-ΔM51-GFP replication in PDAC cell lines
occurs via modiﬁcation of a cellular environment (inhibition of
antiviral signaling), rather than virus-speciﬁc mechanisms. There-
fore, we reasoned that the identiﬁed inhibitors should stimulate
not only VSV but also other OVs. To test this hypothesis, we
examined Sendai virus (SeV, a paramyxovirus), another promising
OV (Kinoh et al., 2004; Kinoh and Inoue, 2008; Komaru et al.,
2009; Yonemitsu et al., 2008). Importantly, our previous study
demonstrated that all VSV-resistant PDAC cell lines were also
resistant to SeV (Murphy et al., 2012). In addition, we examined
the effect of inhibitors on VSV and SeV in two VSV-permissive
PDAC cell lines. Evaluating possible adverse effects of the inhibi-
tors in cells permissive to virus replication would allow us to
determine whether OV/ruxolitinib and/or OV/TPCA-1 combina-
tions can be effectively used against all PDACs, regardless of their
type I IFN status.
VSV-ΔM51-GFP and SeV-GFP-Fmut (described in Materials and
Methods) were tested in HPAF-II, Hs766T, and two VSV-susceptible
(AsPC-1 and MiaPaCa-2) PDAC cell lines. Cells were infected with
VSV-ΔM51-GFP or SeV-GFP-Fmut at MOI of 1 (based on virus
titration on BHK-21 cells, Fig. 8 legend indicates cell speciﬁc MOIs),
and treated with no drug or with TPCA-1, ruxolitinib or JAK Inh. I.
GFP ﬂuorescence was measured through 12 days p.i. due to the
slow SeV-Fmut replication kinetics (Fig. 8). TPCA-1, ruxolitinib and
JAK Inh. I enhanced VSV and SeV replication in both VSV-resistant
PDA cell lines. Interestingly, TPCA-1 and ruxolitinib (and to a less
degree JAK Inh. I) also enhance SeV-GFP-Fmut replication, but not
VSV-ΔM51-GFP, in MiaPaCa-2 cells. Importantly, none of the
inhibitors negatively impacted VSV or SeV replication in both
susceptible cell lines.
Discussion
In this study, we identiﬁed two small molecule inhibitors that
overcome resistance of PDAC cells to oncolytic VSV. TPCA-1 and
ruxolitinib, which have not been previously tested in PDAC in
combination with any virus, enhanced VSV replication and virus-
mediated cell death. Signiﬁcantly, these inhibitors were effective
in all VSV-resistant PDACs, and also enhanced replication of SeV.
Importantly, we demonstrated on a molecular level that TPCA-1, a
well characterized IKK-β inhibitor, is also a direct inhibitor of type
I IFN signaling by directly inhibiting JAK1 kinase activity, down-
regulating expression of antiviral ISGs independently from its
effect on the NF-κB pathway.
Our data provide a new evidence that the upregulated type I
interferon signaling plays a major role in resistance of pancreatic
cancer cells to oncolytic viruses, which is in agreement with a
growing number of reports indicating that a signiﬁcant percentage
of cancers retain active type I IFN signaling, virus-induced antiviral
ISG expression, or even constitutive expression of many ISGs
(Escobar-Zarate et al., 2013; Linge et al., 1995; Matin et al., 2001;
Naik and Russell, 2009; Pfeffer et al., 1996; Saloura et al., 2010;
Stojdl et al., 2003, 2000; Sun et al., 1998; Wong et al., 1997). Our
previous studies using a panel of 11 human PDAC cell lines showed
that 4 of them (36%) constitutively express several antiviral ISGs,
including MxA and OAS (Moerdyk-Schauwecker et al., 2013), and
were resistant to VSV and other OVs (Moerdyk-Schauwecker et al.,
2013; Murphy et al., 2012). Importantly, a signiﬁcant subset of
tested clinical PDAC tissues and xenografted primary PDAC cells
had upregulation of ISGs expression such as MxA (Monsurro et al.,
2010), indicating the existence of this phenotype in the PDAC
patient population.
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In our previous study we showed that a pan-JAK inhibitor,
JAK Inh. I, reduced ISG expression in all VSV-resistant PDAC
cell lines and partially overcame their resistance to VSV (Moerdyk-
Schauwecker et al., 2013). Ruxolitinib, one of the effective inhibitors
identiﬁed in the present study, is also a JAK inhibitor, but with much
greater speciﬁcity towards JAK1 and JAK2 (IC50 of 3.3 and 2.8 nM for
JAK1 and JAK2 respectively, and 4130-fold for JAK3 over JAK1 and
JAK2) than JAK Inh. I (Quintas-Cardama et al., 2010). Ruxolitinib was
more effective than JAK Inh. I in overcoming resistance of all VSV-
resistant PDAC cell lines to VSV. Importantly, ruxolitinib is approved
for the treatment of myeloﬁbrosis (a bone marrow cancer)
(Mascarenhas and Hoffman, 2013; Quintas-Cardama and Verstovsek,
2013), and is currently being investigated against pancreatic cancer
in two different clinical trials (NCT01822756 and NCT01423604).
Moreover, ruxolitinib was shown to enhance VSV-GFP and VSV-
ΔM51-GFP replication, and virus-mediated oncolysis in human head
and neck cancer cells (Escobar-Zarate et al., 2013).
While the identiﬁcation of ruxolitinib is signiﬁcant, it is not
unexpected considering that its mechanism of action is similar to
that of JAK Inh. I. We ﬁnd more surprising a comparable enhance-
ment of VSV replication in all VSV-resistant PDAC cell lines by
TPCA-1, a well-known potent IKK-β inhibitor, but not by any other
tested inhibitor of the NF-κB pathway, including other IKK inhibitors.
TPCA-1 and other NF-κB inhibitors were included in the inhibitor
screen as we hypothesized that upregulation of NF-κB, a hallmark of
PDACs, could be responsible for the constitutive ISG expression in
VSV-resistant cell lines. Constitutive activation of the canonical NF-
κB (RelA/p50) pathway occurs in almost 70% of PDAC specimens
(Wang et al., 1999), and it promotes tumorigenesis (Fujioka et al.,
2003; Ling et al., 2012). Moreover, speciﬁcally for PDACs, a mechan-
istic link has been demonstrated between a common PDACmutation,
KRAS (G12D), and IKK-β activation (Ling et al., 2012).
Despite this role of NF-κB signaling in PDAC tumorigenesis, our
data strongly suggests a direct, NF-κB independent, inhibition of
JAK/STAT signaling by TPCA-1 as: (1) all other IKK inhibitors, while
inhibiting NF-κB activation, did not inhibit MxA expression or
increase VSV replication in resistant PDAC cell lines (Supplementary
Fig. 1A and Fig. 4B); (2) TPCA-1 treatment directly inhibited STAT1
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Fig. 7. Kinetics of VSV replication, MxA expression and apoptosis induction in HPAF-II cells treated with TPCA-1, ruxolitinib or JAK Inh. I. Cells were infected with VSV-ΔM51-
GFP at cell speciﬁc MOI 0.01 for 1 h, then treated with TPCA-1 (8 μM), ruxolitinib (2.5 μM) or JAK Inh. I (2.5 μM) immediately after virus removal. Treatment was maintained
until the end of the experiment. Cells were harvested at each time point and lysates were prepared and analyzed by Western blot for the indicated protein.
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and STAT2 phosphorylation induced by exogenously added IFN-α,
and blocked ISRE binding upon stimulation with IFN-α (Fig. 6B and
C); (3) treatment with TNF-α did not increase ISG expression
(Fig. 6A); (4) ruxolitinib and TPCA-1 acted antagonistically at all
but the lowest concentrations used, suggesting both inhibitors
affect the same downstream target(s) essential for VSV replication
(Fig. 5B); (5) despite targeting two different signaling pathways in
the cell, TPCA-1 and JAK inhibitors showed surprisingly similar
effects on ISG expression and VSV replication (Figs. 1–7); (6) in situ
kinase assay provided a biochemical evidence that TPCA-1 directly
inhibits JAK1 kinase activity (Fig. 6D). To the best of our knowledge,
this is the ﬁrst demonstration that TPCA-1 directly inhibits the
formation of an active ISGF3 complex and thus inhibits type I IFN
signaling.
Fig. 8. TPCA-1, ruxolitinib and JAK Inh. I enhance replication of SeV. Cells were infected with VSV-ΔM51-GFP or SeV-GFP-Fmut at MOI 1 (based on BHK-21 cells), and treated
with TPCA-1 (8 μM), ruxolitinib (2.5 μM) or JAK Inh. I (2.5 μM). Cell-speciﬁc MOIs are MOI 0.00068 based on HPAF-II, MOI 0.0018 based on Hs766T, MOI 0.024 based on AsPC-
1 and MOI 0.066 based on Mia PaCa-2. GFP ﬂuorescence was measured and background ﬂuorescence from uninfected treated cells was subtracted at each time point p.i. The
assays were done in triplicate and data represent the mean7SD of mean. Statistical signiﬁcances (po0.05) between treatment (T: TPCA-1, R: ruxolitinib, J: JAK Inh. I) and no
treated cells (no drug) at 72 h (*) and 148 h (#) are indicated.
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Interestingly, Du et. al. previously examined the effects of
TPCA-1 and BMS-345541 (another IKK inhibitor) on type I IFN
antiviral activity and viral replication in several human glioma cell
lines, and showed that both inhibitors selectively inhibited IFN
stimulated expression of some ISGs, such as MxA and GBP1, and
attenuated IFN-induced antiviral state against VSV and encepha-
lomyocarditis virus (EMCV) (Du et al., 2012). They concluded that
since both inhibitors are IKK inhibitors, the IKK complex, which
lies upstream of NF-κB activation, must play an important role in
IFN induced gene expression and antiviral activity. In agreement
with their hypothesis, their treatment of glioma cells with BMS-
345541 did not prevent STAT1 and STAT2 phosphorylation in cells
treated with IFN-α. Unfortunately, the same experiment with
TPCA-1 was omitted. In contrast to the glioma study, our experi-
ments in PDAC cells show that TPCA-1 enhances VSV replication
and inhibits ISG expression in NF-κB independent manner,
through a direct inhibition on the JAK/STAT signaling pathway.
Also, our results showed no effect of BMS-345541 on constitutive
and IFN-induced expression of MxA (Fig. 4) and on VSV replication
(Supplementary Fig. 1A), suggesting that BMS-345541, as a speciﬁc
IKK inhibitor, is unable to inhibit type I IFN-mediated antiviral
action in PDAC cells. One important difference between PDAC cells
used in our study and glioma cells used in the glioma study
(Du et al., 2012) is that VSV-resistant PDAC cells display constitu-
tive high-level expression of ISGs, while glioma cells did not. This
may explain the differences between our results.
Our data clearly show that TPCA-1 inhibits IFN-mediated
phosphorylation of STAT1 and STAT2 in PDAC cells, and is able to
directly inhibit JAK1 kinase activity in situ. Interestingly, previous
studies proposed two alternative activities for TPCA-1, in addition
to IKK-β inhibition. Thus, a study using HEK-293T cells proposed
TPCA-1 as a direct inhibitor of STAT3 phosphorylation by a
mechanism of direct binding of TPCA-1 to the SH2 domain of
STAT3 and preventing the docking of STAT3 to the membrane
complex (Nan et al., 2014). Another study in hepatocytes also
reported inhibition of STAT3 phosphorylation in presence of TPCA-
1, but through a mechanism of direct inhibition of JAK2 (the kinase
of STAT3) (Saez-Rodriguez et al., 2011). Based on an in vitro kinase
activity assay of puriﬁed recombinant JAK2 [using Fms-like tyr-
osine kinase 3 (FLT3) as a JAK2 substrate] and IKK-β (using IκB as a
IKK-β substrate), TPCA-1 was shown to inhibit JAK2 (Ki about
9 nM) almost as potently as IKK-β (Ki about 1.6 nM). However,
these reports about JAK2 and STAT3 inhibition by TPCA-1 may not
exclude each other, as both JAK (Leonard and O'Shea, 1998; Radtke
et al., 2005; Saez-Rodriguez et al., 2011) and STAT family members
contain SH2 domains (a structurally conserved protein domain in
many signal-transducing proteins that allow proteins containing
those domains to dock to phosphorylated tyrosine residues on
other proteins), and many STAT inhibitors have low speciﬁcity due
to the high homology of the STAT family members (Szelag et al.,
2014). Therefore, we cannot exclude the possibilities that, in
addition to direct inhibition of JAK1, TPCA-1 also: (1) inhibits
JAK2 in PDAC cells; (2) interacts with STAT1 and STAT2 and
prevents their docking to the IFN-α⧸β receptor. It should be also
noted that, although the inhibition of JAK1 kinase activity alone
can explain our results, we cannot rule out the possibility that
TPCA-1 also inhibits TYK2, a kinase very similar to JAK1 and
generally a target for the same inhibitors affecting JAK1 (51–53).
Future experiments should examine relative inhibitory activities of
TPCA-1 against various JAK family members, which is beyond the
scope of the present study.
An important potential advantage of using TPCA-1 over speciﬁc
JAK inhibitors (such as ruxolitinib) is its dual inhibitory activity. On
one hand, TPCA-1 improves efﬁcacy of OV therapies by inhibiting
expression of antiviral ISGs and enhancing virus replication and virus-
mediated oncolysis, while on the other, inhibits NF-κB pathway,
which is an important anticancer approach against PDAC and other
cancers [reviewed in (Carbone and Melisi, 2012; Erstad and Cusack,
2013; Kim et al., 2006; Luo et al., 2005)]. Disregulated activation of
NF-κB plays a major role in tumor development through maintained
expression of target genes that regulate cell growth, proliferation and
survival (Basseres and Baldwin, 2006; Karin, 2006).
Ruxolitinib and TPCA-1 also strongly enhanced replication of
another RNA virus, SeV, in VSV-resistant PDAC cell lines. Impor-
tantly, none of the inhibitors negatively impacted VSV or SeV
replication in virus-permissive PDAC cell lines, suggesting that the
inhibitors do not have side effects on viral replication in PDAC cells
with defective type I IFN signaling, and that the approach
combining OVs with TPCA-1, ruxolitinib or JAK Inh. I could
enhance OV efﬁcacy against virus-resistant PDACs without com-
promising it in virus-permissive PDACs.
It is important to be aware that inhibition of innate antiviral
responses may result in increase of virulence in normal tissues.
However, previously combined treatments of viruses with small
molecule inhibitors of antiviral responses were examined in vivo
and showed promising results. For example, the mammalian
target of rapamycin (mTOR) stimulates type I IFN production via
phosphorylation of its effectors. VSV-ΔM51 in combination with
rapamycin, the inhibitor of mTOR, selectively killed tumor, but not
normal cells and increased the survival of immunocompetent rats
bearing malignant gliomas. Also, HDAC inhibitors inﬂuence epige-
netic changes within cells and can alter gene expression affecting
antiviral responses. Using VSV-ΔM51 in combination with MS-275
or SAHA reversibly compromised host antiviral responses and
enhanced spread of VSV in various cancer types, with no detection
of infected normal tissues (Nguyên et al., 2008; Shestakova et al.,
2001; Shulak et al., 2014). Interestingly, in our study neither
rapamycin nor HDAC inhibitors were able to overcome resistance
of PDAC cells to VSV, suggesting that different mechanisms are
responsible for ISG expression in PDAC cells compared to other
cancer types.
Our future in vivo experiments will address the efﬁcacy and
safety of combined treatments of VSV with TPCA-1 or ruxolitinib.
Based on our in vitro data, it is likely that the inhibitor would need
to be co-administered with the OV and removed after a ﬁnite
period of time to prevent spread of the virus to normal tissues. JAK
1/2 inhibitors are known to reversibly bind to the ATP-binding site
of JAK1 and JAK2 to prevent activation of JAKs and other proteins
in the JAK/STAT signaling pathway (Mascarenhas et al., 2012;
Thompson et al., 2002). Our data are consistent with the reversi-
bility of treatment using JAK inhibitors, since once removed before
infection, the treatment does not enhance VSV replication. Impor-
tantly, similar reversible effect was also demonstrated for TPCA-1
in this study.
Materials and methods
Cell lines, viruses and inhibitors
The human PDAC cell lines used in this study were: CFPAC-1
(ATCC CRL-1918), HPAC (ATCC CRL-2119), HPAF-II (ATCC CRL-1997),
Hs766T (ATCC HTB-134), Mia PaCa-2 (ATCC CRL-1420), and AsPC-1
(ATCC CRL-1682). Baby hamster kidney BHK-21 ﬁbroblast (ATCC
CCL-10) and African green monkey kidney Vero cells (ATCC CCL-
81) were used to grow viruses and determine virus titers. CFPAC-1,
HPAC, Hs766T, Mia PaCa-2, and Vero cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM, Cellgro); AsPC-1 in
RPMI 1640 (HyClone); HPAF-II, and BHK-21 in modiﬁed Eagle’s
medium (MEM, Cellgro). All cell culture media were supplemented
with 10% fetal bovine serum (FBS, Gibco), 4 mM L-glutamine
(Cellgro), 100 IU/ml penicillin-100 μg/ml streptomycin (Cellgro)
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and 1 MEM Nonessential Amino Acids (Cellgro). MEM was also
supplemented with 3.5% glucose. Cells were kept in a 5% CO2
atmosphere at 37 1C. For all experiments, PDAC cell lines were
passaged no more than 10 times.
The recombinant VSV-ΔM51-GFP, which has been described
previously (Wollmann et al., 2010), has a deletion of the methio-
nine at amino acid position 51 of the matrix protein, and the green
ﬂuorescent protein (GFP) ORF inserted at position 5 of the viral
genome (between the VSV G and L genes). The recombinant
Sendai virus (SeV) SeV-GFP-Fmut, which has been described pre-
viously (Wiegand et al., 2007), has the GFP ORF at position 1 of the
viral genome and a mutation in the cleavage site of the fusion
(F) protein, allowing F activation and production of infectious virus
particles in cells without acetylated trypsin added to the medium.
VSV-ΔM51-GFP was grown on BHK-21 cells and SeV-GFP-Fmut was
grown in Vero cells. Viral titers for both viruses were determined
by standard plaque assay on BHK-21 and expressed as plaque-
forming units (PFU) per ml.
JAK Inh. I, IKK-2 Inhibitor VIII, IKK Inhibitor XIII, U-0126,
rapamycin, and valproic acid were purchased from EMD Millipore.
TPCA-1 was purchased from Tocris Bioscience and Sigma-Aldrich.
SC-514, IKK-16 and IMD-0354 were purchased from Tocris
Bioscience. Bortezomib, SAHA (vorinostat), celecoxib and ruxoliti-
nib were purchased from Selleck Chemicals. Sulfasalazine and
BMS-345541 were purchased from Sigma-Aldrich.
Effect of inhibitors on virus replication and cell viability
Cells were seeded in media with 10% FBS in 96-well plate so
that they reached approximately 80% conﬂuence after 24 h (h).
Cells were treated with no drug (here and elsewhere treatment
with no drug contained 0.3% DMSO) or with inhibitor (here and
elsewhere inhibitor treatment also contained 0.3% DMSO) in
culture media with 5% FBS for 48 h prior to infection, or as
speciﬁed. Media was removed and replaced with fresh inhibitor
containing media every 24 h if treatment prior to infection lasted
more than 24 h. Cells were then mock infected or infected with
VSV-ΔM51-GFP or SeV-GFP-Fmut in DMEM without FBS at the
speciﬁed multiplicity of infection (MOI), calculated based on virus
titration on each cell line. Virus-containing media was aspirated
after 1 h absorption period, and replaced with growth media
containing 5% FBS and same inhibitor treatment as prior to
infection, or as speciﬁed. After infection, virus-driven GFP ﬂuor-
escence was measured at regular intervals (CytoFluor Series 4000,
excitation ﬁlter of 485/20 nm, emission 530/25 nm, gain¼63;
Applied Biosystems). Cell viability was analyzed 5 days post
infection (p.i.) by a 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-
tetrazolium bromide (MTT) cell viability assay (Sigma-Aldrich). For
ﬂow cytometry analysis (Beckman Coulter), cells were seeded in 6-
well plate, treated with no drug or inhibitors and infected as
described above. Two days p.i. cells were trypsinized, washed with
ice-cold phosphate-buffered saline (PBS), and ﬁxed with 4%
paraformaldehyde in PBS on ice.
Treatment with multiple inhibitors and Chou–Talalay analysis
HPAF-II and Hs766T cells were seeded as described above, and
treated with no drug or two-fold serial dilutions of TPCA-1,
ruxolitinib or both inhibitors in combination. Concentrations
ranged from 2 to 16 μM for TPCA-1 and 1 to 8 μM for ruxolitinib.
After 24 h pre-treatment, cells were mock infected or infected
with VSV-ΔM51-GFP in DMEM without FBS at an MOI of 0.001.
Virus-containing media was aspirated after 1 h, and replaced with
growth media containing 5% FBS and same treatment as prior to
infection. After infection, VSV-driven GFP ﬂuorescence was mea-
sured every 24 h for 4 days. Dose–effect curves for each inhibitor
and Combination Indices (CIs) for each combination of inhibitors
were calculated by the Chou and Talalay CI method (Chou, 2006;
Chou and Talalay, 1984) using CompuSyn software, version 1.0
(ComboSyn Inc., Paramus, New Jersey) and a non-constant ratio
design. The fraction affected was calculated by subtracting back-
ground ﬂuorescence (cells treated with no drug), and normalizing
each value to the maximum GFP ﬂuorescence value reached for
each cell line over the 4 days treatment. For TPCA-1 and JAK Inh. I
combination treatment, HPAF-II, HPAC and Hs766T cells were
either treated with no drug or with 8 μM TPCA-1, 2.5 μM JAK
Inh. I, 4 μM BMS-345541 or TPCA-1 and JAK Inh. I combined, for
2 days before infection with VSV-ΔM51-GFP at an MOI of 15
(based on titration on BHK-21 cells; Fig. 5 legend indicates cell
speciﬁc MOIs). Cells were harvested 2 days p.i. and cell lysates
were prepared and analyzed by Western blot as described below.
Protein isolation and Western blot analysis
Cells were seeded in a 6-well as described above and treated
with no drug or with the speciﬁed inhibitor until they were
harvested. Where indicated, after 2 h inhibitor treatment, cells
were treated with 25 ng/ml of a recombinant human Tumor
Necrosis Factor Alpha (TNF-α R&D systems) or 5000 U/ml IFN
alpha (IFN-α EMD Millipore) for 4 h. For time-course, cells were
ﬁrst infected with VSV-ΔM51-GFP at MOI of 0.01, and then treated
with no drug or with inhibitor until harvested. Media was
removed and cells were lysed in lysis buffer containing 0.0625 M
Tris-HCl (pH 6.8), 10% glycerol, 2% SDS, 5% 2-mercaptoethanol, and
0.02% (w/v) bromophenol blue. Total protein was separated by
electrophoresis on SDS-PAGE gels and electroblotted to polyviny-
lidene diﬂuoride (PVDF) membranes. Membranes were blocked
using 5% non-fat powdered milk in TBS-T [0.5 M NaCl, 20 mM Tris
(pH 7.5), 0.1% Tween20]. Membranes were incubated with 1:5000
rabbit polyclonal anti-VSV antibodies (raised against VSV virions),
1:1000 rabbit anti-MxA (Sigma-Aldrich, SAB1100070), 1:200 rab-
bit anti-OAS (Santa Cruz, sc-99097), 1:1000 rabbit anti-PARP1
(Santa Cruz, sc-25780), 1:500 rabbit anti-p-STAT2 (R&D Systems,
MAB2890) and the following antibodies from Cell Signaling
Technology (1:1000 or 1:500): STAT1 (9172), p-STAT1 (7649),
STAT2 (4594), STAT3 (9139), p-STAT3 (9134), IkBα (4814), p-IkBα
(2859), and Caspase 3 (9662) in TBS-T with 5% BSA or milk with
0.02% sodium azide. The 1:2000 goat anti-mouse or 1:2000 goat
anti-rabbit horseradish peroxidase-conjugated secondary antibo-
dies (Jackson-ImmunoResearch) were used. The Amersham ECL
Western Blotting Detection Kit (GE Healthcare) or Pierce Super-
Signal WestPico Detection Kit (Thermo Scientiﬁc) was used for
detection. To verify total protein in each loaded sample, mem-
branes were re-probed with rabbit anti-GAPDH antibody (Santa
Cruz, sc-25778) or stained with Coomassie blue R-250.
RNA isolation and analysis
HPAF-II cells were seeded in a 6-well plate as described above and
treated with no drug or with the speciﬁed inhibitor for 2 h in serum
free-media (SFM). Cells were then treated with TNF-α (25 ng/ml) or
IFN-α (5000 U/ml) for 4 h, while inhibitor treatment was maintained.
IFN-α and TNF-α induction was performed in SFM to exclude
nonspeciﬁc NF-κB activation by serum components. Total RNA was
extracted using the Quick-RNA Mini Prep kit in accordance with
manufacturer instructions (Zymo Research), and reverse transcribed
using SMART-Scribe reverse transcriptase (Clontech Laboratories, Inc.)
and random hexamer as per manufacturer's protocol. PCR products
were electrophoresed on a 2% agarose gel with ethidium bromide and
photographed using a GelDoc-It imager (UVP Imaging). Real-time PCR
were run in triplicate using Absolute Blue SYBR Green Rox Mix
(Thermo Scientiﬁc) in an Applied Biosystems 7500 sequence
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detection system. Relative gene expression was normalized to GAPDH
expression and fold change expression was calculated by the com-
parative Ct method. The following primers were used for PCR and/or
real-time PCR: β-actin: 50-gcaaagacctgtacgccaaca-30 (forward),
50-cctcggccacattgtgaac-30 (reverse); TNF-α 50-cccagggacctctctctaatca
(forward), 50-gcttgagggtttgctacaacatg-30 (reverse); MxA: 50-gctaca-
caccgtgacggatatgg-30 (forward), 50-cgagctggattggaaagccc-30 (reverse);
OAS2: 50-tcagaagagaagccaacgtga-30 (forward), 50-cggagacagcgaggg-
taaat-30 (reverse); GAPDH: 50-ccatcaccatcttccaggagcgag-30 (forward),
50-cacagtcttctgggtggcagtgat-30 (reverse). IFN-β: 50-ggcaattgaatgg-
gaggct-30 (forward), 50-ggcgtcctccttctggaact-30 (reverse).
Nuclei isolation and EMSA analysis
HPAF-II cells were seeded in a 6-well plate as described above, and
treated with no drug or with 8 μM TPCA, 2.5 μM ruxolitinib, or
2.5 μM JAK Inh. I for 2 h prior to inductionwith IFN-α (5000 U/ml) for
the indicated time. Nuclear protein extracts were isolated as pre-
viously described (Holden and Tacon, 2011), and the protein concen-
tration determined by Bradford assay. A double-stranded
oligonucleotide corresponding to the consensus ISRE for STAT1/2
binding (50-ggcttcagtttcggtttccctttcccgagg-30) was end-labeled with
[γ-32P]ATP using T4 kinase (Promega). Nuclear extracts containing
5 μg of nuclear protein were incubated with radiolabeled ISRE probe
and 1 μg poly(dI-dC) in binding buffer (20 mM HEPES pH 7.9, 1 mM
DTT, 0.1 mM EDTA, 50 mM KCl, 5% glycerol, and 200 μg/ml BSA) for
20 min at room temperature and subjected to 4% non-denaturing
PAGE in 0.5 Tris-borate-EDTA buffer. The gel was vacuum dried and
subjected to autoradiography.
JAK1 kinase assay
100 ng/well of puriﬁed active recombinant human JAK1 kinase
(Life Technologies, cat. No. PV4774) was incubated for 1 h with
serial 3-fold dilutions of inhibitors, 5 μM ATP and 0.2 μg/μl Poly
E4Y1 as substrate (Sigma) in kinase reaction buffer [40 mM Tris
(pH 7.5), 20 mM MgCl2, and 0.1 mg/ml BSA]. Reaction was per-
formed in a total volume of 25 μl in a solid white ﬂat-bottom 96-
well plate. Kinase activity was assayed using an ADP-Glo Kinase
Assay (Promega). Assay was done in duplicates for each inhibitor,
and curve ﬁtting was performed using Graph Pad Prism sigmoidal
dose–response (variable slope) software.
Statistical analysis
All statistical analyses were performed using GraphPad Prism,
version 5.03 for Windows (GraphPad Software, San Diego, California).
Unpaired or multiple t-tests were used for comparison between
groups and p values of o0.05 were considered signiﬁcant.
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